Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiochem, Inc.

Latest From Angiochem, Inc.

Pipeline Watch: Phase III Starts With Filgotinib, Gilteritinib And Nivolumab

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical Trials

From LSD To GD To PD


Geron CEO: Getting Imetelstat Data Wanted By FDA Will Be “Difficult”

Concerned about chronic liver injury, FDA halts development of Geron’s telomerase inhibitor imetelstat, the only drug left standing in Geron’s pipeline, and requests data for patients who discontinued treatment in Geron-sponsored plus non-Geron studies.

Clinical Trials

And then there was one: GRN1005 failure leaves Geron with imetelstat and $90m

The good news for Geron's investors? Now that the Menlo Park, California-based company has terminated development of GRN1005 and plans to lay off 64 of its 107 employees, it has enough cash on hand to fund its operations for two or three years.

Cancer Chad
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule